We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Article Submission Process Streamlined for Clinica Chimica Acta and Related Journals

By LabMedica International staff writers
Posted on 26 Sep 2022
Image: The Article Transfer Service is designed to help manuscripts find the right journal faster (Photo courtesy of Elsevier)
Image: The Article Transfer Service is designed to help manuscripts find the right journal faster (Photo courtesy of Elsevier)

Submitting an article for a scientific publication is an essential step in the research process, but finding the right journal can be challenging. Often authors' first choice of journal turns out not to be the right one, requiring them to resubmit their article elsewhere, which can be a complex and time-consuming process.

Now, an initiative by Elsevier BV (Amsterdam, Netherlands), one of the world's largest scientific publishers with around 300 journals including Clinica Chimica Acta, recognizes this process isn’t always smooth, and aims to help authors find the best journal match for their article, quickly and easily.

To achieve this, a dedicated team of scientific editors use their subject-matter knowledge to analyze manuscripts, provide guidance and tailored recommendations for transfers to another Elsevier journal, working closely with editors from both originating and destination journals.

Authors who have received rejections, either before or after peer review, will be able to accept a transfer offer to a more suitable journal.

The program is designed to make the editorial process smoother and more efficient, so that transferred articles will flow through the Elsevier editorial submission system. This comes with the advantage that in many instances, authors won’t need to reformat the article but still have the option to make revisions if they want. Additionally, previous comments from editors and referees can be transmitted with the manuscript, ensuring all parties benefit from previous insights.

The most common types of transmissions are pre-review and post-review, where editors of the destination journal will make their own assessment based on the materials they receive. When the editor of the originating journal considers that an article is acceptable for publication in another journal, Elsevier's scientific managing editor can offer an enhanced offer to authors such as Recommended Acceptance, Guaranteed Peer-Review or Fast-Track Processing by the suggested journal.

For Recommended Acceptance, provided that authors address comments from the original editors/referees, and follow the instructions given in the transfer offer, publication in the alternative journal is expected without further peer review. Laura Guilherme Luzia, a scientific managing editor at Clinica Chimica Acta, added, "Elsevier's Article Transfer Service team understands that authors are unique, and that each article deserves to find its most suitable journal."

Related Links:
Elsevier BV 
Clinica Chimica Acta 
Elsevier Article Transfer Service 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)

Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more